On Jan. 14, 2021, Cepheid that Health Canada announced that it had issued Cepheid a medical device license for Xpertﾮ Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample.

The test was available in Canada and can be used in laboratories and at the point of care. The four-in-one test was designed for use on any of Cepheid’s almost 30,000 GeneXpertﾮ Systems placed worldwide, with results delivered in approximately 36 minutes.